NRAS MUTATION
Clinical trials for NRAS MUTATION explained in plain language.
Never miss a new study
Get alerted when new NRAS MUTATION trials appear
Sign up with your email to follow new studies for NRAS MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a malaria drug boost immunotherapy for a tough skin cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether adding hydroxychloroquine—a drug commonly used for malaria—to a MEK inhibitor (tunlametinib) and an immunotherapy (pucotenlimab) can improve outcomes for people with advanced NRAS-mutant melanoma. The study aims to see if this combination can…
Matched conditions: NRAS MUTATION
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New targeted drug hopes to shrink NRAS-Driven cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…
Matched conditions: NRAS MUTATION
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC